Literature DB >> 24389079

Dose optimisation of antibiotics in children: application of pharmacokinetics/pharmacodynamics in paediatrics.

Kevin J Downes1, Andrea Hahn1, Jason Wiles2, Joshua D Courter3, Alexander A Vinks4.   

Abstract

The judicious use of antibiotics to combat infections in children relies upon appropriate selection of an agent, dose and duration to maximise efficacy and to minimise toxicity. Critical to dose optimisation is an understanding of the pharmacokinetics and pharmacodynamics of available drugs. Optimal dosing strategies may take advantage of pharmacokinetic/pharmacodynamic (PK/PD) principles so that antibiotic dosing can be individualised to assure effective bacterial killing in patients who have altered pharmacokinetics or who have infections with less susceptible or resistant organisms. This review will outline the fundamentals of antimicrobial pharmacokinetics/pharmacodynamics through discussion of antibacterial agents most often used in children. We aim to highlight the importance of dose optimisation in paediatrics and describe non-conventional dosing strategies that can take advantage of PK/PD principles at the bedside.
Copyright © 2013 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

Entities:  

Keywords:  Antibiotics; Dose optimisation; PK/PD; Pharmacodynamics; Pharmacokinetics

Mesh:

Substances:

Year:  2013        PMID: 24389079      PMCID: PMC3965635          DOI: 10.1016/j.ijantimicag.2013.11.006

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  78 in total

Review 1.  Drug disposition in cystic fibrosis.

Authors:  E Rey; J M Tréluyer; G Pons
Journal:  Clin Pharmacokinet       Date:  1998-10       Impact factor: 6.447

2.  Pharmacokinetic-pharmacodynamic model for gentamicin and its adaptive resistance with predictions of dosing schedules in newborn infants.

Authors:  Ami F Mohamed; Elisabet I Nielsen; Otto Cars; Lena E Friberg
Journal:  Antimicrob Agents Chemother       Date:  2011-10-28       Impact factor: 5.191

3.  Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients.

Authors:  Tomohiro Sasaki; Hiroshi Takane; Katsuhiro Ogawa; Sayaka Isagawa; Takeshi Hirota; Shun Higuchi; Toshinobu Horii; Kenji Otsubo; Ichiro Ieiri
Journal:  Antimicrob Agents Chemother       Date:  2011-02-28       Impact factor: 5.191

4.  Single dose pharmacokinetics of linezolid in infants and children.

Authors:  G L Kearns; S M Abdel-Rahman; J L Blumer; M D Reed; L P James; R F Jacobs; J A Bradley; I R Welshman; G L Jungbluth; D J Stalker
Journal:  Pediatr Infect Dis J       Date:  2000-12       Impact factor: 2.129

5.  Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections.

Authors:  Pamela A Moise-Broder; Alan Forrest; Mary C Birmingham; Jerome J Schentag
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

6.  Improved vancomycin dosing in children using area under the curve exposure.

Authors:  Jennifer Le; John S Bradley; William Murray; Gale L Romanowski; Tu T Tran; Natalie Nguyen; Susan Cho; Stephanie Natale; Ivilynn Bui; Tri M Tran; Edmund V Capparelli
Journal:  Pediatr Infect Dis J       Date:  2013-04       Impact factor: 2.129

7.  Incidence of amikacin ototoxicity: a sigmoid function of total drug exposure independent of plasma levels.

Authors:  A R Beaubien; S Desjardins; E Ormsby; A Bayne; K Carrier; M J Cauchy; R Henri; M Hodgen; J Salley; A St Pierre
Journal:  Am J Otolaryngol       Date:  1989 Jul-Aug       Impact factor: 1.808

8.  Pharmacokinetic modelling of a once-daily dosing regimen for intravenous tobramycin in paediatric cystic fibrosis patients.

Authors:  Wallace Lam; James Tjon; Winnie Seto; Allison Dekker; Cecile Wong; Eshetu Atenafu; Ari Bitnun; Valerie Waters; Yvonne Yau; Melinda Solomon; Felix Ratjen
Journal:  J Antimicrob Chemother       Date:  2007-04-19       Impact factor: 5.790

Review 9.  Continuous and extended infusions of β-lactam antibiotics in the pediatric population.

Authors:  Mary Covington Walker; Weng Man Lam; Kalen B Manasco
Journal:  Ann Pharmacother       Date:  2012-10-31       Impact factor: 3.154

10.  The antibiotic resistance and prescribing in European Children project: a neonatal and pediatric antimicrobial web-based point prevalence survey in 73 hospitals worldwide.

Authors:  Ann Versporten; Mike Sharland; Julia Bielicki; Nico Drapier; Vanessa Vankerckhoven; Herman Goossens
Journal:  Pediatr Infect Dis J       Date:  2013-06       Impact factor: 2.129

View more
  22 in total

Review 1.  Determining the optimal vancomycin daily dose for pediatrics: a meta-analysis.

Authors:  Geisa Cristina da Silva Alves; Samuel Dutra da Silva; Virginia Paula Frade; Danielle Rodrigues; André de Oliveira Baldoni; Whocely Victor de Castro; Cristina Sanches
Journal:  Eur J Clin Pharmacol       Date:  2017-08-04       Impact factor: 2.953

2.  Relationship of Pulmonary Outcomes, Microbiology, and Serum Antibiotic Concentrations in Cystic Fibrosis Patients.

Authors:  Andrea Hahn; Caroline Jensen; Hani Fanous; Hollis Chaney; Iman Sami; Geovanny F Perez; Stan Louie; Anastassios C Koumbourlis; James E Bost; John N van den Anker
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Sep-Oct

Review 3.  Clinical Pharmacokinetics of Amikacin in Pediatric Patients: A Comprehensive Review of Population Pharmacokinetic Analyses.

Authors:  Sílvia M Illamola; Catherine M Sherwin; J G Coen van Hasselt
Journal:  Clin Pharmacokinet       Date:  2018-10       Impact factor: 6.447

Review 4.  How to Treat Sepsis in the Background of Resistance?: Role of Pharmacodynamics / Pharmacokinetics in Treating Sepsis.

Authors:  Mohit Agrawal; Ashok Rattan
Journal:  Indian J Pediatr       Date:  2020-01-14       Impact factor: 1.967

5.  Population Pharmacokinetic Models of Vancomycin in Paediatric Patients: A Systematic Review.

Authors:  Erin Chung; Jonathan Sen; Priya Patel; Winnie Seto
Journal:  Clin Pharmacokinet       Date:  2021-05-18       Impact factor: 6.447

6.  Pharmacokinetic modelling to predict risk of ototoxicity with intravenous tobramycin treatment in cystic fibrosis.

Authors:  Min Dong; Anna V Rodriguez; Chelsea A Blankenship; Gary McPhail; Alexander A Vinks; Lisa L Hunter
Journal:  J Antimicrob Chemother       Date:  2021-10-11       Impact factor: 5.790

7.  Development and validation of a UHPLC-MS/MS method to measure cefotaxime and metabolite desacetylcefotaxime in blood plasma: a pilot study suitable for capillary microsampling in critically ill children.

Authors:  Yarmarly C Guerra Valero; Tavey Dorofaeff; Jason A Roberts; Jeffrey Lipman; Mark G Coulthard; Louise Sparkes; Steven C Wallis; Suzanne L Parker
Journal:  Anal Bioanal Chem       Date:  2021-05-26       Impact factor: 4.142

8.  Prospective Evaluation of a Model-Based Dosing Regimen for Amikacin in Preterm and Term Neonates in Clinical Practice.

Authors:  A Smits; R F W De Cock; K Allegaert; S Vanhaesebrouck; M Danhof; C A J Knibbe
Journal:  Antimicrob Agents Chemother       Date:  2015-07-27       Impact factor: 5.191

Review 9.  Suggestions for Model-Informed Precision Dosing to Optimize Neonatal Drug Therapy.

Authors:  Joshua C Euteneuer; Suyog Kamatkar; Tsuyoshi Fukuda; Alexander A Vinks; Henry T Akinbi
Journal:  J Clin Pharmacol       Date:  2018-09-11       Impact factor: 3.126

10.  Optimized antimicrobial dosing strategies: a survey of pediatric hospitals.

Authors:  Chad A Knoderer; Kristen R Nichols; Elaine G Cox
Journal:  Paediatr Drugs       Date:  2014-12       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.